In the first human trial of a new therapeutic, a single injection of lepodisiran reduced levels of lipoprotein(a), or Lp(a), to undetectable levels for nearly one year, according to late-breaking ...
Even after stopping treatment with the novel small interfering RNA (siRNA) olpasiran (Amgen), patients experience sustained lowering of lipoprotein(a) for almost 1 year, according to new phase II data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback